Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

NCT06405087 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06405087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06405087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Recruiting
Start date
October 27, 2025
Completion date
August 12, 2030
Enrollment
70 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, ulcerative colitis